NASDAQ: MGRX · Industrial Applications and Services · 5 alerts · CIK 1938046
Share price
$0.1603Close, Nov 16
Market cap
$3.46M
Shares outstanding
21.57MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Misc Health & Allied Services, NECSIC 8090
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Mangoceuticals, Inc. filings on SEC EDGAR ↗
Mangoceuticals, Inc. is a smaller reporting company and emerging growth company focused on scaling its operations and marketing its products. The filing highlights significant risks including a limited operating history, the need for additional funding, and reliance on third-party compounding pharmacies for products not approved by the FDA.
Mangoceuticals amended its Series B and Series C preferred stock designations and established a new Series D Preferred Stock class. The Series D Preferred Stock will rank senior to common stock and existing preferred classes regarding dividends and liquidation, though no shares were issued at the time of filing. The amendments include waivers from existing preferred holders to allow for the senior ranking and future Series D transactions.
Mangoceuticals, Inc. received written consent from its Series B Preferred Stock holder to establish a new series of 8% Series D Convertible Cumulative Preferred Stock. The company plans to offer up to 1,000,000 shares of the Series D Preferred Stock at $10.00 per share through a Regulation A offering. The Series B holder also approved an amendment to recognize the senior dividend and liquidation rights of the new Series D shares.
Mangoceuticals, Inc. entered into a securities purchase agreement for a registered direct offering of 657,000 shares of common stock and accompanying warrants to purchase up to 657,000 additional shares. The offering was priced at $0.75 per unit, representing a 74% premium to the recent market close, and is expected to generate gross proceeds of approximately $492,750 for working capital and general corporate purposes.
Mangoceuticals Divestiture to Two accredited investors for $2.5M
Mangoceuticals, Inc. sold a 25% ownership stake in its subsidiary, MangoRx IP Holdings, LLC, to two accredited investors for $2.5 million. The transaction was structured at the subsidiary level to raise capital for the commercialization of its antiviral technology (MGX-0024) without diluting the parent company's common stock.